Brought to you by 
Novartis announces MOU to buy Advanced Accelerator Applications for $3.9bn; later tenders offer
03 Sep 2020
Executive Summary
Confirming rumors that began circulating late last month, Novartis AG entered a memorandum of understanding (MOU) to tender an all-cash offer for all outstanding shares of public French biotech Advanced Accelerator Applications SA (AAA; diagnostic and therapeutic radiopharmaceuticals). The AAA board has already approved the MOU.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis announces MOU to buy Advanced Accelerator Applications for $3.9bn; later tenders offer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice